Ustekinumab could be approved to treat ulcerative colitis
Ustekinumab has been submitted to be the first interleukin (IL)-12/23…
Ustekinumab has been submitted to be the first interleukin (IL)-12/23 inhibitor licensed for the treatment of ulcerative colitis...